1
|
Upadhyay P, Wu CW, Pham A, Zeki AA, Royer CM, Kodavanti UP, Takeuchi M, Bayram H, Pinkerton KE. Animal models and mechanisms of tobacco smoke-induced chronic obstructive pulmonary disease (COPD). JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH. PART B, CRITICAL REVIEWS 2023; 26:275-305. [PMID: 37183431 PMCID: PMC10718174 DOI: 10.1080/10937404.2023.2208886] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, and its global health burden is increasing. COPD is characterized by emphysema, mucus hypersecretion, and persistent lung inflammation, and clinically by chronic airflow obstruction and symptoms of dyspnea, cough, and fatigue in patients. A cluster of pathologies including chronic bronchitis, emphysema, asthma, and cardiovascular disease in the form of hypertension and atherosclerosis variably coexist in COPD patients. Underlying causes for COPD include primarily tobacco use but may also be driven by exposure to air pollutants, biomass burning, and workplace related fumes and chemicals. While no single animal model might mimic all features of human COPD, a wide variety of published models have collectively helped to improve our understanding of disease processes involved in the genesis and persistence of COPD. In this review, the pathogenesis and associated risk factors of COPD are examined in different mammalian models of the disease. Each animal model included in this review is exclusively created by tobacco smoke (TS) exposure. As animal models continue to aid in defining the pathobiological mechanisms of and possible novel therapeutic interventions for COPD, the advantages and disadvantages of each animal model are discussed.
Collapse
Affiliation(s)
- Priya Upadhyay
- Center for Health and the Environment, University of California, Davis, Davis, CA 95616 USA
| | - Ching-Wen Wu
- Center for Health and the Environment, University of California, Davis, Davis, CA 95616 USA
| | - Alexa Pham
- Center for Health and the Environment, University of California, Davis, Davis, CA 95616 USA
| | - Amir A. Zeki
- Department of Internal Medicine; Division of Pulmonary, Critical Care, and Sleep Medicine, Center for Comparative Respiratory Biology and Medicine, School of Medicine; University of California, Davis, School of Medicine; U.C. Davis Lung Center; Davis, CA USA
| | - Christopher M. Royer
- California National Primate Research Center, University of California, Davis, Davis, CA 95616 USA
| | - Urmila P. Kodavanti
- Public Health and Integrated Toxicology Division, Center for Public Health and Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC 27711, USA
| | - Minoru Takeuchi
- Department of Animal Medical Science, Kyoto Sangyo University, Kyoto, Japan
| | - Hasan Bayram
- Koc University Research Center for Translational Medicine (KUTTAM), School of Medicine, Istanbul, Turkey
| | - Kent E. Pinkerton
- Center for Health and the Environment, University of California, Davis, Davis, CA 95616 USA
| |
Collapse
|
2
|
Lim CS, Veltri B, Kashon M, Porter DW, Ma Q. Multi-walled carbon nanotubes induce arachidonate 5-lipoxygenase expression and enhance the polarization and function of M1 macrophages in vitro. Nanotoxicology 2023; 17:249-269. [PMID: 37115655 DOI: 10.1080/17435390.2023.2204161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
Fibrogenic carbon nanotubes (CNTs) induce the polarization of M1 and M2 macrophages in mouse lungs. Polarization of the macrophages regulates the production of proinflammatory and pro-resolving lipid mediators (LMs) to mediate acute inflammation and its resolution in a time-dependent manner. Here we examined the molecular mechanism by which multi-walled CNTs (MWCNTs, Mitsui-7) induce M1 polarization in vitro. Treatment of murine macrophages (J774A.1) with Mitsui-7 MWCNTs increased the expression of Alox5 mRNA and protein in a concentration- and time-dependent manner. The MWCNTs induced the expression of CD68 and that induction persisted for up to 3 days post-exposure. The expression and activity of inducible nitric oxide synthase, an intracellular marker of M1, were increased by MWCNTs. Consistent with M1 polarization, the MWCNTs induced the production and secretion of proinflammatory cytokines tumor necrosis factor-α and interleukin-1β, and proinflammatory LMs leukotriene B4 (LTB4) and prostaglandin E2 (PGE2). The cell-free media from MWCNT-polarized macrophages induced the migration of neutrophilic cells (differentiated from HL-60), which was blocked by Acebilustat, a specific leukotriene A4 hydrolase inhibitor, or LY239111, an LTB4 receptor antagonist, but not NS-398, a cyclooxygenase 2 inhibitor, revealing LTB4 as a major mediator of neutrophil chemotaxis from MWCNT-polarized macrophages. Knockdown of Alox5 using specific small hairpin-RNA suppressed MWCNT-induced M1 polarization, LTB4 secretion, and migration of neutrophils. Taken together, these findings demonstrate the polarization of M1 macrophages by Mitsui-7 MWCNTs in vitro and that induction of Alox5 is an important mechanism by which the MWCNTs promote proinflammatory responses by boosting M1 polarization and production of proinflammatory LMs.
Collapse
Affiliation(s)
- Chol Seung Lim
- Receptor Biology Laboratory, Toxicology and Molecular Biology Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, WV, USA
| | - Brandon Veltri
- Department of Microbiology, Immunology, and Cell Biology, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, WV, USA
| | - Michael Kashon
- Bioanalytics Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, WV, USA
| | - Dale W Porter
- Pathology and Physiology Research Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, WV, USA
| | - Qiang Ma
- Receptor Biology Laboratory, Toxicology and Molecular Biology Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, WV, USA
| |
Collapse
|
3
|
Gao H, Li J, Chen X, Sun Z, Cui G, Cheng M, Ding L. Pharmacokinetics, metabolite profiling, safety, and tolerability of inhalation aerosol of 101BHG-D01, a novel, long-acting and selective muscarinic receptor antagonist, in healthy Chinese subjects. Front Pharmacol 2022; 13:1064364. [PMID: 36588683 PMCID: PMC9797597 DOI: 10.3389/fphar.2022.1064364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2022] [Accepted: 11/21/2022] [Indexed: 12/23/2022] Open
Abstract
101BHG-D01 is a novel, long-acting, selective muscarinic receptor antagonist for the treatment of chronic obstructive pulmonary disease (COPD). A single-site, randomized, double-blind, placebo-controlled and dose-escalation study of 101BHG-D01 inhalation aerosol was conducted to evaluate its pharmacokinetics, metabolite profiling, safety and tolerability following the single inhaled doses ranged from 20 to 900 μg in healthy Chinese subjects. After inhalation, 101BHG-D01 was absorbed rapidly into plasma with the time to maximum concentration about 5 min, and eliminated slowly with the terminal phase half-life about 30 h. The cumulative excretion rates of 101BHG-D01 in feces and urine were about 30% and 2%, respectively, which showed the study drug was mainly excreted in feces. The maximum drug concentration and area under the plasma concentration-time curve increased with dose escalation in the range of 20-600 μg, but their values increased out of proportion to the whole studied doses. The main metabolic pathways were loss of phenyl group and hydroxylation. No metabolite that presented at greater than 10 percent of total drug-related exposure was observed. 101BHG-D01 was safe and well tolerated after administration. The study results indicate that 101BHG-D01 is a good candidate for the treatment of COPD and enable further clinical development in subsequent studies in patients. Clinical Trial Registration: http://www.chinadrugtrials.org.cn; Identifier: CTR20192058.
Collapse
Affiliation(s)
- Huaye Gao
- Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China
| | - Jintong Li
- Drug Clinical Trial Research Center, China-Japan Friendship Hospital, Beijing, China,*Correspondence: Li Ding, ; Jintong Li,
| | - Xiaoping Chen
- Beijing Shuobai Pharmaceutical Technology Co., Ltd., Beijing, China
| | - Zhanguo Sun
- Beijing Shuobai Pharmaceutical Technology Co., Ltd., Beijing, China
| | - Gang Cui
- Drug Clinical Trial Research Center, China-Japan Friendship Hospital, Beijing, China
| | - Minlu Cheng
- Nanjing Jiening Pharmaceutical Technology Co., Ltd., Nanjing, China
| | - Li Ding
- Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China,*Correspondence: Li Ding, ; Jintong Li,
| |
Collapse
|
4
|
Sarcinelli MA, Martins da Silva T, Artico Silva AD, Ferreira de Carvalho Patricio B, Mendes de Paiva FC, Santos de Lima R, Leal da Silva M, Antunes Rocha HV. The pulmonary route as a way to drug repositioning in COVID-19 therapy. J Drug Deliv Sci Technol 2021; 63:102430. [PMID: 33649708 PMCID: PMC7903910 DOI: 10.1016/j.jddst.2021.102430] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2020] [Revised: 02/04/2021] [Accepted: 02/12/2021] [Indexed: 12/12/2022]
Abstract
Introduction The outbreak of the disease caused by the new coronavirus (COVID-19) has been affecting society's routine and its patterns of interaction worldwide, in addition to the impact on the global economy. To date, there is still no clinically effective treatment for this comorbidity, and drug repositioning might be a good strategy considering the established clinical safety profile. In this context, since COVID-19 affects the respiratory tract, a promising approach would be the pulmonary drug delivery. Objective Identify repurposing drug candidates for the treatment of COVID-19 based on the data of ongoing clinical trials and in silico studies and also assess their potential to be applied in formulations for pulmonary administration. Method A integrative literature review was conducted between June and July 2020, by extracting the results from Clinical Trials, PubMed, Web of Science and Science Direct databases. Results By crossing the results obtained from diverse sources, 21 common drugs were found, from which only 4 drugs presented studies of pulmonary release formulations, demonstrating the need for greater investment and incentive in this field. Conclusion Even though the lung is a target that facilitates viral infection and replication, formulations for pulmonary delivery of suitable drugs are still lacking for COVID-19 treatment. However, it is indisputable that the pandemic constitutes a concrete demand, with a profound impact on public health, and that, with the appropriate investments, it will give the pharmaceutical industry an opportunity to reinforce the pulmonary delivery field.
Collapse
Affiliation(s)
- Michelle Alvares Sarcinelli
- Laboratório de Micro e Nanotecnologia, Instituto de Tecnologia Em Fármacos (Farmanguinhos), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, 21040-361, Brazil.,Rede Rio de Inovação em Nanossistemas para a Saúde - NanoSAÚDE/ FAPERJ, Rio de Janeiro, RJ, Brazil
| | - Thalita Martins da Silva
- Laboratório de Micro e Nanotecnologia, Instituto de Tecnologia Em Fármacos (Farmanguinhos), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, 21040-361, Brazil.,Rede Rio de Inovação em Nanossistemas para a Saúde - NanoSAÚDE/ FAPERJ, Rio de Janeiro, RJ, Brazil.,Programa de Pós-graduação em Pesquisa Translacional em Fármacos e Medicamentos, Instituto de Tecnologia em Fármacos (Farmanguinhos), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, 21040-361, Brazil
| | - Andressa Daniele Artico Silva
- Laboratório de Micro e Nanotecnologia, Instituto de Tecnologia Em Fármacos (Farmanguinhos), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, 21040-361, Brazil.,Rede Rio de Inovação em Nanossistemas para a Saúde - NanoSAÚDE/ FAPERJ, Rio de Janeiro, RJ, Brazil
| | - Beatriz Ferreira de Carvalho Patricio
- Laboratório de Micro e Nanotecnologia, Instituto de Tecnologia Em Fármacos (Farmanguinhos), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, 21040-361, Brazil.,Rede Rio de Inovação em Nanossistemas para a Saúde - NanoSAÚDE/ FAPERJ, Rio de Janeiro, RJ, Brazil
| | - Flávia Costa Mendes de Paiva
- Laboratório de Micro e Nanotecnologia, Instituto de Tecnologia Em Fármacos (Farmanguinhos), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, 21040-361, Brazil.,Rede Rio de Inovação em Nanossistemas para a Saúde - NanoSAÚDE/ FAPERJ, Rio de Janeiro, RJ, Brazil.,Programa de Pós-graduação em Pesquisa Translacional em Fármacos e Medicamentos, Instituto de Tecnologia em Fármacos (Farmanguinhos), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, 21040-361, Brazil
| | - Raissa Santos de Lima
- Programa de Pós-Graduação em Biologia Computacional e Sistemas, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, 21041-361, Brazil
| | - Manuela Leal da Silva
- Programa de Pós-Graduação em Biologia Computacional e Sistemas, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, 21041-361, Brazil.,Instituto de Biodiversidade e Sustentabilidade (NUPEM), Universidade Federal Do Rio de Janeiro, Macaé, RJ, 27965-045, Brazil
| | - Helvécio Vinícius Antunes Rocha
- Laboratório de Micro e Nanotecnologia, Instituto de Tecnologia Em Fármacos (Farmanguinhos), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, 21040-361, Brazil.,Rede Rio de Inovação em Nanossistemas para a Saúde - NanoSAÚDE/ FAPERJ, Rio de Janeiro, RJ, Brazil.,Programa de Pós-graduação em Pesquisa Translacional em Fármacos e Medicamentos, Instituto de Tecnologia em Fármacos (Farmanguinhos), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, 21040-361, Brazil
| |
Collapse
|
5
|
Laudette M, Zuo H, Lezoualc'h F, Schmidt M. Epac Function and cAMP Scaffolds in the Heart and Lung. J Cardiovasc Dev Dis 2018; 5:jcdd5010009. [PMID: 29401660 PMCID: PMC5872357 DOI: 10.3390/jcdd5010009] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2018] [Revised: 01/25/2018] [Accepted: 01/29/2018] [Indexed: 12/13/2022] Open
Abstract
Evidence collected over the last ten years indicates that Epac and cAMP scaffold proteins play a critical role in integrating and transducing multiple signaling pathways at the basis of cardiac and lung physiopathology. Some of the deleterious effects of Epac, such as cardiomyocyte hypertrophy and arrhythmia, initially described in vitro, have been confirmed in genetically modified mice for Epac1 and Epac2. Similar recent findings have been collected in the lung. The following sections will describe how Epac and cAMP signalosomes in different subcellular compartments may contribute to cardiac and lung diseases.
Collapse
Affiliation(s)
- Marion Laudette
- Inserm UMR-1048, Institut des Maladies Métaboliques et Cardiovasculaires, Université Toulouse III, 31432 Toulouse, France.
| | - Haoxiao Zuo
- Department of Molecular Pharmacology, University of Groningen, 9713AV Groningen, The Netherlands.
- Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, 9713AV Groningen, The Netherlands.
| | - Frank Lezoualc'h
- Inserm UMR-1048, Institut des Maladies Métaboliques et Cardiovasculaires, Université Toulouse III, 31432 Toulouse, France.
| | - Martina Schmidt
- Department of Molecular Pharmacology, University of Groningen, 9713AV Groningen, The Netherlands.
- Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, 9713AV Groningen, The Netherlands.
| |
Collapse
|
6
|
Pini A, Boccalini G, Lucarini L, Catarinicchia S, Guasti D, Masini E, Bani D, Nistri S. Protection from Cigarette Smoke-Induced Lung Dysfunction and Damage by H2 Relaxin (Serelaxin). J Pharmacol Exp Ther 2016; 357:451-8. [PMID: 27048661 DOI: 10.1124/jpet.116.232215] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2016] [Accepted: 04/04/2016] [Indexed: 12/16/2023] Open
Abstract
Cigarette smoke (CS) is the major etiologic factor of chronic obstructive pulmonary disease (COPD), which is characterized by airway remodeling, lung inflammation and fibrosis, emphysema, and respiratory failure. The current therapies can improve COPD management but cannot arrest its progression and reduce mortality. Hence, there is a major interest in identifying molecules susceptible of development into new drugs to prevent or reduce CS-induced lung injury. Serelaxin (RLX), or recombinant human relaxin-2, is a promising candidate because of its anti-inflammatory and antifibrotic properties highlighted in lung disease models. Here, we used a guinea pig model of CS-induced lung inflammation, and remodeling reproducing some of the hallmarks of COPD. Animals exposed chronically to CS (8 weeks) were treated with vehicle or RLX, delivered by osmotic pumps (1 or 10 μg/day) or aerosol (10 μg/ml/day) during CS treatment. Controls were nonsmoking animals. RLX maintained airway compliance to a control-like pattern, likely because of its capability to counteract lung inflammation and bronchial remodeling. In fact, treatment of CS-exposed animals with RLX reduced the inflammatory recruitment of leukocytes, accompanied by a significant reduction of the release of proinflammatory cytokines (tumor necrosis factor α and interleukin-1β). Moreover, RLX was able to counteract the adverse bronchial remodeling and emphysema induced by CS exposure by reducing goblet cell hyperplasia, smooth muscle thickening, and fibrosis. Of note, RLX delivered by aerosol has shown a comparable efficacy to systemic administration in reducing CS-induced lung dysfunction and damage. In conclusion, RLX emerges as a new molecule to counteract CS-induced inflammatory lung diseases.
Collapse
Affiliation(s)
- Alessandro Pini
- Anatomy and Histology Section and Histology and Embryology Research Unit, Department of Experimental and Clinical Medicine (A.P., G.B., S.C., D.G., D.B., S.N.), and Pharmacology Section, Department NEUROFARBA (L.L., E.M.), University of Florence, Florence, Italy
| | - Giulia Boccalini
- Anatomy and Histology Section and Histology and Embryology Research Unit, Department of Experimental and Clinical Medicine (A.P., G.B., S.C., D.G., D.B., S.N.), and Pharmacology Section, Department NEUROFARBA (L.L., E.M.), University of Florence, Florence, Italy
| | - Laura Lucarini
- Anatomy and Histology Section and Histology and Embryology Research Unit, Department of Experimental and Clinical Medicine (A.P., G.B., S.C., D.G., D.B., S.N.), and Pharmacology Section, Department NEUROFARBA (L.L., E.M.), University of Florence, Florence, Italy
| | - Stefano Catarinicchia
- Anatomy and Histology Section and Histology and Embryology Research Unit, Department of Experimental and Clinical Medicine (A.P., G.B., S.C., D.G., D.B., S.N.), and Pharmacology Section, Department NEUROFARBA (L.L., E.M.), University of Florence, Florence, Italy
| | - Daniele Guasti
- Anatomy and Histology Section and Histology and Embryology Research Unit, Department of Experimental and Clinical Medicine (A.P., G.B., S.C., D.G., D.B., S.N.), and Pharmacology Section, Department NEUROFARBA (L.L., E.M.), University of Florence, Florence, Italy
| | - Emanuela Masini
- Anatomy and Histology Section and Histology and Embryology Research Unit, Department of Experimental and Clinical Medicine (A.P., G.B., S.C., D.G., D.B., S.N.), and Pharmacology Section, Department NEUROFARBA (L.L., E.M.), University of Florence, Florence, Italy
| | - Daniele Bani
- Anatomy and Histology Section and Histology and Embryology Research Unit, Department of Experimental and Clinical Medicine (A.P., G.B., S.C., D.G., D.B., S.N.), and Pharmacology Section, Department NEUROFARBA (L.L., E.M.), University of Florence, Florence, Italy
| | - Silvia Nistri
- Anatomy and Histology Section and Histology and Embryology Research Unit, Department of Experimental and Clinical Medicine (A.P., G.B., S.C., D.G., D.B., S.N.), and Pharmacology Section, Department NEUROFARBA (L.L., E.M.), University of Florence, Florence, Italy
| |
Collapse
|